Turn Therapeutics Inc.

NasdaqGM:TTRX Stock Report

Market Cap: US$132.2m

Turn Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Bradley Burnam

Chief executive officer

US$429.3k

Total compensation

CEO salary percentage100.00%
CEO tenure7.3yrs
CEO ownership54.4%
Management average tenureno data
Board average tenure6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bradley Burnam's remuneration changed compared to Turn Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$4m

Jun 30 2025n/an/a

-US$3m

Mar 31 2025n/an/a

-US$2m

Dec 31 2024US$429kUS$429k

-US$2m

Sep 30 2024n/an/a

-US$2m

Jun 30 2024n/an/a

-US$2m

Mar 31 2024n/an/a

-US$2m

Dec 31 2023US$429kUS$429k

-US$2m

Compensation vs Market: Bradley's total compensation ($USD429.32K) is about average for companies of similar size in the US market ($USD587.00K).

Compensation vs Earnings: Bradley's compensation has been consistent with company performance over the past year.

CEO

Bradley Burnam (45 yo)

7.3yrs
Tenure
US$429,320
Compensation

Mr. Bradley E. Burnam is Founder & CEO of Turn Therapeutics, Inc. (Global Health Solutions, Inc.) and serves as its Director since October 2018. He is responsible for the development of Turn’s multiple FDA...

Board Members

NamePositionTenureCompensationOwnership
Bradley Burnam
Founder7.3yrsUS$429.32k54.39%
$ 71.9m
Neilesh Ghodadra
Chief Medical Officer & Director7.3yrsno data0%
$ 0
Arthur Golden
Independent Directorless than a yearno data0.17%
$ 227.2k
Andrew Gengos
Independent Director6yrsno data0%
$ 0
Kent Kester
Independent Directorless than a yearno datano data
6.0yrs
Average Tenure
61yo
Average Age

Experienced Board: TTRX's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/07 23:52
End of Day Share Price 2026/01/07 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Turn Therapeutics Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.